OBJECTIVE: To evaluate the diagnostic significance of Fascin protein in non-small cell lung cancer (NSCLC) patients.METHODS: Among 110 cases of NSCLC patients and 50 cases of healthy controls, double antibody sandwich enzyme-linked immunosorbent assay (ELISA) was employed to measure the serum levels of Fascin protein, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), scales like squamous cell carcinoma (SCC) antigen, cytokeratin protein 21-1 (CYFRA21-1) and gastrin-releasing peptide (GRP) precursor. Fascin-positive rate (24.4%) in NSCLC patients was significantly higher than that in healthy controls (4%) (P < 0.05).In different clinical stages of non-small cell lung cancer patients, Fascin-positive rate was statistically significant (P < 0.05). The positive rates of Fascin for CEA, CYFRA21-1, NSE, SCC and Pro-GRP were 25.64%, 5.1%, 5.1%, 5.0% and 1.7% respectively.CONCLUSION: As a new tumor marker, Fascin may be used for clinical screening and prognosis in lung cancer.
Adult Aged